{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:39:48Z","timestamp":1772771988033,"version":"3.50.1"},"reference-count":143,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2020,8,2]]},"DOI":"10.1080\/17474086.2020.1797482","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T12:54:10Z","timestamp":1594904050000},"page":"871-883","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies"],"prefix":"10.1080","volume":"13","author":[{"given":"Tsering Gyalpo","family":"Lama","sequence":"first","affiliation":[{"name":"UI Health","place":["Orange, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kyung","sequence":"additional","affiliation":[{"name":"UI Health","place":["Orange, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"UI Health","place":["Orange, USA"]},{"name":"Chao Family Comprehensive Cancer Center, UCI Health","place":["Orange Country, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442"},{"key":"e_1_3_4_4_1","unstructured":"Statistics Review 1975\u20132016. 2019 Aug. Available from: https:\/\/seer.cancer.gov\/csr\/1975_2016\/"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-639161"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.2.448"},{"key":"e_1_3_4_7_1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow SH","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon (FR): IARC Press; 2008."},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0131-2"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31931"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404441"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-586826"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71182-9"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7520"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810044"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00741.x"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.021908.132541"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-012-0254-8"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-362624"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.343"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.1969.173"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(71)92742-5"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0888-7543(90)90562-9"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJICMR.S71779"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000175"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600221"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.03.062"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1404027"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0358-1"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0313-y"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2020.1724282"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-59"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2225"},{"key":"#cr-split#-e_1_3_4_45_1.1","unstructured":"FDA Expands Approved Use of ibrutinib for chronic lymphocytic leukemia. updated 2014 Jul 28"},{"key":"#cr-split#-e_1_3_4_45_1.2","unstructured":"cited 2020 Feb 04. Available from: https:\/\/www.ascopost.com\/News\/17440"},{"key":"e_1_3_4_46_1","unstructured":"Dangi-Garimella S. Phase 3 RESONATE-2 data yield first-line approval for ibrutinib in CLL. AJMC. Newsroom. 2016 Mar 4 [cited 2020 Jan 18]. Available from: https:\/\/www.ajmc.com\/newsroom\/phase-3-resonate-2-data-yields-first-line-approval-for-ibrutinib-in-cll"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0438-x"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.01.006"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24021"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4345"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2019.1594777"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7040062"},{"key":"e_1_3_4_53_1","unstructured":"Imbruvica prescribing information. Sunnyvale CA: Pharmacyclics May 2015 [cited 2020 Feb 08]. Available from: https:\/\/www.janssenmd.com\/pdf\/imbruvica\/PI-Imbruvica.pdf. opens in new tab"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3599"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.15171\/apb.2017.041"},{"issue":"6","key":"e_1_3_4_57_1","first-page":"261","article-title":"Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure","volume":"58","author":"Lippert TH","year":"2008","unstructured":"Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung. 2008;58(6):261\u2013264.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761536"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-585075"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13427"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018029058"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1402716"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000854"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003632"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3435"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219550"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-592725"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1409362111"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6840"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"#cr-split#-e_1_3_4_80_1.1","unstructured":"ClinicalTrials.gov. Venetoclax and ibrutinib in treating in participants with chronic lymphocytic leukemia and ibrutinib resistance mutations. NCT03513562. 2018 May 1 [updated 2020 Mar 28"},{"key":"#cr-split#-e_1_3_4_80_1.2","unstructured":"cited 2020 Jan 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03513562"},{"key":"#cr-split#-e_1_3_4_81_1.1","unstructured":"ClinicalTrials.gov. Ibrutinib and venetoclax in treating patients with chronic lymphocytic leukemia after ibrutinib resistance. NCT03943342. 2019 May 9 [updated 2020 Mar 13"},{"key":"#cr-split#-e_1_3_4_81_1.2","unstructured":"cited 2020 Feb 03]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03943342"},{"key":"e_1_3_4_82_1","first-page":"157","article-title":"Zydelig (Idelalisib): first-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies","volume":"8","author":"Raedler LA","year":"2015","unstructured":"Raedler LA. Zydelig (Idelalisib): first-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies. Am Health Drug Benefits. 2015;8(SpecFeature):157\u2013162.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph12020069"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3335.3335"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx031"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00512-0"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121834"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4399.4399"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3232.3232"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1409"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127260"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126114"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.07.081"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127509"},{"key":"e_1_3_4_97_1","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-15-C186","article-title":"Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation","volume":"14","author":"Binnerts ME","year":"2015","unstructured":"Binnerts ME, Otipoby KL, Hopkins B, et al. Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation. Mol Cancer Ther. 2015;14:C186-C. Available from: https:\/\/mct.aacrjournals.org\/content\/14\/12_Supplement_2\/C186","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126286"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-693598"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7502"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121424"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026617"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1101\/509158"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.2427.2427"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-737346"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147900"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.06.001"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0453-8"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127280"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2017-044"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-622936"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1500712112"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-765685"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30217-5"},{"key":"e_1_3_4_118_1","unstructured":"ClinicalTrials.gov. Nivolumab and ibrutinib in treating patients with relapsed refractory or high-risk untreated chronic lymphocytic leukemia small lymphocytic lymphoma or Richter transformation. NCT02420912. 17 May 2019 [cited 2020 Jan 28] Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02420912"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118148"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7530"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0313-8"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-603670"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1602268"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25436"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_3_4_127_1","first-page":"595060","article-title":"Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia","volume":"2012","author":"Koehler P","year":"2011","unstructured":"Koehler P, Schmidt P, Hombach AA, et al. Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol. 2011;2012:595060.","journal-title":"Adv Hematol"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25457"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.56.56"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115418"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmonc.2012.09.019"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-304683"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14700"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2018-0010"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0187"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-610782"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1159\/000477338"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2464"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.60.60"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4108"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2020.1797482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:32:36Z","timestamp":1772767956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2020.1797482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,2]]},"references-count":143,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,2]]}},"alternative-id":["10.1080\/17474086.2020.1797482"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2020.1797482","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}